Accordingly, in terms of platelet-induced drug resistance, apart from targeting relevant platelet-originated factors (e.g., PDGF, TGFβ1, and EGF) and pathways including TGF-β/NF-κB signaling, targeting the activity of platelets in TME is an important approach to improve the sensitivity of tumor therapy. This evidence concerns the gene TGFB1 and neoplasm.